研发的不断变化的景观-IQVIA - 中国竞技竞彩,王者荣耀kpl外围投注,王者荣耀外围竞猜

王者荣耀kpl外围投注
IQVIA研究所
报告
The Changing Landscape of Research and Development

The Changing Landscape of Research and Development

创新，变化的驱动因素和临床试验生产力的发展

Institute Report

2019年4月23日

Download

关于报告

在过去的十年中，创新药物的发展发生了巨大的发展。这项研究评估了2018年研发的活动和景观（R＆D），临床开发过程的生产率水平以及主要试验趋势将如何在未来五年内改变临床开发。研究了新型疗法和管道疗法的特征和开发路径，以及将这些药物投放市场的公司的转变。该报告提出了专有的临床发展生产力指数，该指数反映了试验的复杂性，成功和持续时间的变化。探索了促进临床发展的八种关键趋势，并讨论了2023年对生产率的预期定量影响。

本报告中包括的研究是由IQVIA人类数据科学研究所独立进行的公共服务，没有行业或政府资助。lpl哪里可以下外围本报告中的分析都不是来自专有赞助商试验信息，而是基于专有的IQVIA数据库和/或第三方信息。

Report Charts

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Download 全部下载

Chart 1: New Actives Substances (NAS) Launched for the First Time in the United States in 2018

Chart 1: New Actives Substances (NAS) Launched for the First Time in the United States in 2018

Chart 2: Features of the Trials Cited in Approvals of NASs Launched the United States in 2018

Chart 2: Features of the Trials Cited in Approvals of NASs Launched the United States in 2018

图3：引用的试验中包括的患者年平均数量，以批准2018年启动的NASS

图3：引用的试验中包括的患者年平均数量，以批准2018年启动的NASS

Chart 4: Median Time from First Patent Filing to Launch by NAS Launch Year, United States

Chart 4: Median Time from First Patent Filing to Launch by NAS Launch Year, United States

图5：公司和公司申请FDA监管提交的创始公司和公司

图5：公司和公司申请FDA监管提交的创始公司和公司

Chart 6: Number of Late-Stage Pipeline Products by Therapeutic Drug Class, 2009−2018

Chart 6: Number of Late-Stage Pipeline Products by Therapeutic Drug Class, 2009−2018

图7：后期管道中的下一代生物治疗管道产品的数量，2009-2018

图7：后期管道中的下一代生物治疗管道产品的数量，2009-2018

Chart 8: Late-Stage Pipeline Products and Changes from 2017 in Selected Classes

Chart 8: Late-Stage Pipeline Products and Changes from 2017 in Selected Classes

图9：公司段的后期管道百分比

Chart 10: U.S. Venture Capital Deal Value in US$Bn and Number of Deals Closed

Chart 10: U.S. Venture Capital Deal Value in US$Bn and Number of Deals Closed

图11：大型制药研发支出和销售百分比，$ $亿美元

Chart 11: Large Pharma R&D Spending and Percentage of Sales, US$BN

图12：所有治疗区域的临床试验数量，并逐步选择治疗区域

图12：所有治疗区域的临床试验数量，并逐步选择治疗区域

图13：从第一阶段开始到阶段结果的平均累积相持续时间

图13：从第一阶段开始到阶段结果的平均累积相持续时间

Chart 14: R&D Composite Success Rate and Average Phase Success Rates Phase I to Filing, 2008−2018

Chart 14: R&D Composite Success Rate and Average Phase Success Rates Phase I to Filing, 2008−2018

图15：2018年的研发综合成功率按治疗区域

Chart 15: R&D Composite Success Rate in 2018 by Therapy Area

图16：临床发展生产率指数

图17：根据治疗区域的所有阶段的试验生产率，2010- 2018年

图17：根据治疗区域的所有阶段的试验生产率，2010- 2018年

Chart 18: Trial Productivity, 2010−2018

Chart 18: Trial Productivity, 2010−2018

Chart 19: Trial Success Rates by Phase, 2010-2018

Chart 19: Trial Success Rates by Phase, 2010-2018

Chart 20: Trial Complexity by Phase and Therapy Area, 2010−2018

Chart 20: Trial Complexity by Phase and Therapy Area, 2010−2018

Chart 21: Average Trial Duration by Phase and Therapy Area, 2010−2018

Chart 21: Average Trial Duration by Phase and Therapy Area, 2010−2018

Chart 22: Select Positive and Negative Events at Registration and Clinical Levels, 2018

Chart 22: Select Positive and Negative Events at Registration and Clinical Levels, 2018

Chart 23: Number of Years Since Product’s First Patent Filing to Discontinuation or Regulatory Approval of Alzheimer’s Therapies

Chart 23: Number of Years Since Product’s First Patent Filing to Discontinuation or Regulatory Approval of Alzheimer’s Therapies

Chart 24: Current NAFLD/NASH Pipeline with Targeted Pathways

Chart 24: Current NAFLD/NASH Pipeline with Targeted Pathways

图25：按阶段和类型进行的神经肌肉疾病管道

图25：按阶段和类型进行的神经肌肉疾病管道

Chart 26: Digital Health Applications Transforming Clinical Development

Chart 26: Digital Health Applications Transforming Clinical Development

图27：临床开发的预测分析和AI驱动价值

图27：临床开发的预测分析和AI驱动价值

Chart 28: Likelihood that Trends will Impact Clinical Development Across Therapy Areas and Impact Timing

Chart 28: Likelihood that Trends will Impact Clinical Development Across Therapy Areas and Impact Timing

图29：趋势的影响和计时区域的可能性

图29：趋势的影响和计时区域的可能性

Chart 30: Trend Timing by Therapy Area in Years

Chart 30: Trend Timing by Therapy Area in Years

Chart 31: Predicted Percent Change in Productivity, Effort and Success from 2018 to 2023 by Trend

Chart 31: Predicted Percent Change in Productivity, Effort and Success from 2018 to 2023 by Trend

Chart 32: Predicted Percent Change in Productivity per Trend by Therapy Area from 2018 to 2023

Chart 32: Predicted Percent Change in Productivity per Trend by Therapy Area from 2018 to 2023

Chart 33: Predicted Percent Change in Productivity per Trend by Therapy Area from 2018 to 2023

Chart 33: Predicted Percent Change in Productivity per Trend by Therapy Area from 2018 to 2023

Chart 34: Average Percent Change in Productivity per Therapy Area from 2018 to 2023 as a Result of Trends

Chart 34: Average Percent Change in Productivity per Therapy Area from 2018 to 2023 as a Result of Trends

Chart 35: Predicted Percent Change in Productivity by Therapy Area and Trend from 2018 to 2023

Chart 35: Predicted Percent Change in Productivity by Therapy Area and Trend from 2018 to 2023

Chart 36: Predicted Percent Change in Productivity from 2018 to 2023 by Phase

Chart 36: Predicted Percent Change in Productivity from 2018 to 2023 by Phase

相关博客

量化研发趋势对试验生产率的影响

Learn more

联系我们

联系我们

联系我们

Email Us

Get in touch today to discover the right solutions for you.

Email Us

Call Us

We are pleased to speak with you during our standard business hours.

仅免费电话
+1 866 267 4479

For international call please find a number in our免费列表.

IQVIA Institute查询

We are ready to help you better understand and benefit from the work of the IQVIA Institute for Human Data Science. Please get in touch today to learn more.

联系我们